Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Appl Radiat Isot ; 94: 182-190, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25216366

ABSTRACT

Microtomographic (µCT) and thin section (TS) images were analyzed and compared regarding porosity and its distribution along the samples. The results show that µCT, although limited by its resolution, shows relevant information about the distribution of porosity and quantification of connected and non-connected pores. TS have no limitations concerning resolution, but are limited by the experimental data and can only give information about connected pores. These two methods have their own advantages but when paired together they are able to make for a more complete analysis.

2.
Clin Pharmacol Ther ; 85(5): 520-6, 2009 May.
Article in English | MEDLINE | ID: mdl-19129748

ABSTRACT

Dapagliflozin selectively inhibits renal glucose reabsorption by inhibiting sodium-glucose cotransporter-2 (SGLT2). It was developed as an insulin-independent treatment approach for type 2 diabetes mellitus (T2DM). The safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug were evaluated in single-ascending-dose (SAD; 2.5-500 mg) and multiple-ascending-dose (MAD; 2.5-100 mg daily for 14 days) studies in healthy subjects. Dapagliflozin exhibited dose-proportional plasma concentrations with a half-life of approximately 17 h. The amount of glucosuria was also dose-dependent. Cumulative amounts of glucose excreted on day 1, relating to doses from 2.5-100 mg (MAD), ranged from 18 to 62 g; day 14 values were comparable to day 1 values, with no apparent changes in glycemic parameters. Doses of approximately 20-50 mg provided close-to-maximal SGLT2 inhibition for at least 24 h. Dapagliflozin demonstrates pharmacokinetic (PK) characteristics and dose-dependent glucosuria that are sustained over 24 h, which indicates that it is suitable for administration in once-daily doses and suggests that further investigation of its efficacy in T2DM patients is warranted.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glucosides/administration & dosage , Glycosuria/chemically induced , Hypoglycemic Agents/administration & dosage , Sodium-Glucose Transporter 2 Inhibitors , Adult , Benzhydryl Compounds , Blood Glucose/drug effects , Diabetes Mellitus, Type 2/physiopathology , Dose-Response Relationship, Drug , Double-Blind Method , Glucosides/adverse effects , Glucosides/pharmacokinetics , Half-Life , Humans , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/pharmacokinetics , Male , Sodium-Glucose Transporter 2 , Time Factors
3.
Vet Rec ; 146(14): 403-6, 2000 Apr 01.
Article in English | MEDLINE | ID: mdl-10791469

ABSTRACT

The expression of hormone receptors and their relationship to cell proliferation in six samples of normal canine mammary tissue, and 11 benign and 10 malignant mammary neoplasms from female dogs were assessed by immunohistochemistry in formalin-fixed paraffin-embedded samples, by using monoclonal antibodies against progesterone and oestrogen receptors, and nuclear antigen Ki-67 (MIB-1). Malignant tumours negative for progesterone receptors proliferated at higher rates than progesterone receptor-positive tumours, suggesting that the progression towards malignancy in spontaneous mammary tumours is accompanied by a decrease in hormonal steroid dependency. Only one malignant tumour was positive for oestrogen receptors.


Subject(s)
Dog Diseases/pathology , Mammary Glands, Animal/pathology , Mammary Neoplasms, Animal/pathology , Receptors, Cell Surface/isolation & purification , Animals , Cell Division , Dogs , Female
4.
Vet J ; 158(1): 39-47, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10409415

ABSTRACT

DNA measurement by image cytometry, and a detailed immunohistochemical study using monoclonal antibodies directed against different human cytokeratin types, muscle-specific actin, vimentin and S100 protein were carried out on normal canine mammary tissue (n =4), benign canine mammary mixed tumours (n =20) and malignant canine mammary mixed tumours (n =13). The results showed that ductal and alveolar luminal cells in normal and neoplastic tissue were immunoreactive with CAM5.2 and AE1/AE3 antibodies recognizing human keratins.Basal/myoepithelial cells were clearly differentiated from ductal and alveolar epithelial cells, since the latter only expressed cytokeratins, whereas the former also expressed vimentin and muscle-specific actin. This immunohistochemical study showed that there is loss of expression of muscle-specific actin and cytokeratins in areas of myoepithelial proliferation, and enhanced expression of vimentin and S100 protein in proliferative areas with osseous and/or chondroid metaplasia. The ploidy studies revealed that 20% (4/20) of benign and 54% (7/13) of malignant mixed tumours of canine mammary gland were aneuploid and that the epithelial and myoepithelial components of the mixed tumours had identical DNA content. Our results reinforce the role of myoepithelial cells in mesenchymal metaplasia in mixed mammary tumours and suggest the possibility of a common origin of both components from a totipotential stem cell with capacity for divergent differentiation.


Subject(s)
Dog Diseases/pathology , Mammary Neoplasms, Animal/pathology , Actins/immunology , Animals , DNA, Neoplasm/chemistry , Dog Diseases/genetics , Dogs , Epithelial Cells/pathology , Female , Image Cytometry/veterinary , Immunohistochemistry , Keratins/immunology , Mammary Neoplasms, Animal/genetics , Mesoderm/pathology , Ploidies , Vimentin/immunology
5.
Rev Port Cardiol ; 11(11): 951-9, 1992 Nov.
Article in Portuguese | MEDLINE | ID: mdl-1290642

ABSTRACT

OBJECTIVE: To evaluate the significance of the fibrinogen, the plasminogen and the fibrinogen degradation products levels as marks of left intraventricular thrombosis (LIVT) in acute myocardial infarction (AMI). METHODS: 219 consecutive patients of AMI admitted in a Coronary Care Unit of an University Hospital, were prospectively studied. All protocols included a clinical evaluation, an M-mode and 2D echocardiographic study and blood samples, at day 1, 3, 7 and at hospital discharge. In the intraventricular thrombus evaluation just the 4 Asinger grade was considered. In the laboratory evaluation we used: the Clauss chronometric method for the fibrinogen, the colorimetric method for the plasminogen and the agglutination in plaque for the FDP. The patients with ECO in the 2 or 3 Asinger grades and those in which ECO and laboratory study were not performed in the same day, were excluded. 101 patients remained on the study, and they were divided in two groups: 53 patients with LIVT and 48 patients without it. RESULTS: In both groups the fibrinogen raised along the first six days of the AMI, however in the group with LIVT this level didn't raise as high as in the group without LIVT (p < 0.001). In the FDP evaluation two peaks were found, one at 48 hours and another on the 6 th day, but there were no differences between the two groups. The plasminogen values raised along the first week of AMI, in a similar way in both groups. CONCLUSIONS: a) Fibrinogen levels raises in AMI, but this elevation is significantly smaller in the group with LIVT, which suggests fibrinogen consume in fibrin formation of the thrombus. b) FDP and plasminogen levels raise along the first week of AMI, but in a similar way in the two groups. c) None of these parameters permitted to individualize patients with thrombus formation.


Subject(s)
Fibrinogen/analysis , Heart Diseases/blood , Myocardial Infarction/complications , Plasminogen/analysis , Thrombosis/blood , Aged , Female , Fibrinogen/metabolism , Heart Diseases/etiology , Heart Ventricles , Humans , Male , Middle Aged , Prospective Studies , Thrombosis/etiology
6.
Rev Port Cardiol ; 10(9): 693-9, 1991 Sep.
Article in Portuguese | MEDLINE | ID: mdl-1747261

ABSTRACT

Hemostatic control is based in a delicate balance between the activities of activator enzymes and their inhibitors, each one depending on a large number of proteins. Plasma Antithrombin III (ATIII) is one of the most important coagulation inhibitors and the fundamental enzyme for the therapeutical action of heparin. In the last years it was well established that ATIII deficiency accounts for a thrombotic state and inefficiency of heparin therapy. In this work, the authors review the biology of ATIII including its biochemical nature, its physiology, physiopathology and mechanism of action, analysing the implications of its deficiency. The authors draw the attention on clinical and laboratory studies that analyse the prevalence and importance of congenital and acquired deficiency of ATIII, in relation to the prevalence of venous thrombosis. Finally, the laboratory methods applied to the study of ATIII and to the biological control of heparin therapy are described with emphasis on the importance of the ATIII concentrates on this type of treatment. Also the fundamental aspects of heparin resistance are specially mentioned.


Subject(s)
Antithrombin III/physiology , Antithrombin III/analysis , Antithrombin III Deficiency , Blood Coagulation/physiology , Drug Resistance , Heparin/analysis , Heparin/pharmacology , Thrombosis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...